What the changes say
- Progyny faces new artificial intelligence operational and regulatory risks.
What changed since the prior 10-K
New
- NewRisks Related to Our Business and Industry
Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challenges
Using artificial intelligence and generative AI tools exposes us to legal, regulatory, ethical, and operational risks, including data flaws and hallucinations.
Dropped
- DroppedRisks Related to Our Business and Industry
We went live with Progyny Rx in 2018, and 91% of our current clients have now launched this solution, including approximately 95% of the clients we signed in 2024
- DroppedRisks Related to Our Business and Industry
If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us, and our competitive position would be harmed
- DroppedRisks Related to Legal and Regulatory Requirements
or clients that do business with government entities, or to refund some or all of our service fees or otherwise compensate our clients
- DroppedRisks Related to Ownership of Our Common Stock
capital to fund continuing operations through the sale of additional equity securities and may impair our ability to make strategic investments, including acquiring other companies or investing in technologies, using our equity as consideration
Reworded
- 86% rewrittenRisks Related to Ownership of Our Common Stock
An active trading market for our common stock may not be sustained
Added equity capital raising and strategic investment impairments due to an inactive trading market.
- 76% rewrittenRisks Related to Our Business and Industry
Our business depends on our ability to retain our existing clients and increase the adoption of our services within our client base. Any failure to do so would harm our business, financial condition and results of operations
Updated Progyny Rx client launch statistics, showing 92% adoption for current clients and 97% for clients signed in 2025.
- 71% rewrittenRisks Related to Legal and Regulatory Requirements
We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business
Maintained regulatory compliance and investigation warnings for operations, clients, and vendors.
- 66% rewrittenRisks Related to Our Business and Industry
Failure to enforce our intellectual property rights could impair our ability to protect our proprietary technology and our brand
Retained core intellectual property protection and confidentiality agreement enforcement risks.
- 31% rewrittenRisks Related to Our Business and Industry
Any of the above factors, alone or together, could negatively affect our ability to retain existing clients and sell additional solutions to them, which would have an adverse effect on our business, revenue growth and results of operations
Updated client count to over 590 employers, noted no client exceeded 10% of revenue in 2025, and disclosed that the 12% client from 2024 terminated effective January 1, 2025.
- 31% rewrittenRisks Related to Our Business and Industry
Changes in our effective tax rate or tax liabilities may have an adverse effect on our results of operations
Replaced the Inflation Reduction Act with the One Big Beautiful Bill Act reference regarding R&D cost expensing and bonus depreciation.
- 28% rewrittenRisks Related to Our Business and Industry
Unfavorable conditions in the global economy or our industry could limit our ability to grow our business and negatively affect our results of operations
Added tariffs, export controls, trade barriers, and global trade wars to macroeconomic and geopolitical risk factors.
- 27% rewrittenRisks Related to Our Business and Industry
Acquisitions, strategic investments, or partnerships could be difficult to identify, pose integration challenges, divert the attention of management, disrupt our business, dilute stockholder value, and adversely affect our business, financial condition and results of operations
Refined descriptions of the Apryl GmbH and Benefit Bump LLC acquisitions and expanded care offerings.
- 27% rewrittenRisks Related to Legal and Regulatory Requirements
We are part of the broader healthcare industry and subject to increasing scrutiny, disclosure requirements and regulation within our business, including with respect to Progyny Rx’s PBM operations, which may adversely affect our business, financial condition and results of operations
Was: We are part of the broader healthcare industry and subject to increasing scrutiny and regulation within our business, including with respect to Progyny Rx’s PBM operations, which may adversely affect our business, financial condition and results of operations
All 53 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business and Industry
- 01We may fail to meet our publicly announced guidance or other expectations about our business and future results of operations, which would cause our stock price to decline
- 02The market in which we operate is highly competitive, and, if we do not continue to compete effectively, our business, financial condition and results of operations could be harmed
- 03Unfavorable conditions in the global economy or our industry could limit our ability to grow our business and negatively affect our results of operations28% rewritten
- 04Our business depends on our ability to retain our existing clients and increase the adoption of our services within our client base. Any failure to do so would harm our business, financial condition and results of operations76% rewritten
- 05Any of the above factors, alone or together, could negatively affect our ability to retain existing clients and sell additional solutions to them, which would have an adverse effect on our business, revenue growth and results of operations31% rewritten
- 06If we are unable to attract new clients, our business, financial condition and results of operations would be adversely affected
- 07A significant change in the utilization of our solutions, including the consumption rate or the mix of utilization, could have an adverse effect on our business, financial condition and results of operations
- 08Acquisitions, strategic investments, or partnerships could be difficult to identify, pose integration challenges, divert the attention of management, disrupt our business, dilute stockholder value, and adversely affect our business, financial condition and results of operations27% rewritten
- 09We have a limited operating history with our current platform of solutions, which makes it difficult to predict our future results of operations
- 10We have a history of operating losses and may not sustain profitability in the future
- 11The health benefits industry may be subject to negative publicity, which could adversely affect our business, financial condition and results of operations
- 12Our use of artificial intelligence may subject us to new or heightened legal, regulatory, ethical, operational or other challengesNew
- 13If we fail to offer high-quality support, our reputation could suffer
- 14Failure to effectively develop and expand our marketing and sales capabilities could harm our ability to increase our client base and achieve broader market acceptance of the solutions we provide
- 15Our future revenue and client base may not grow at the rates they historically have, or at all
- 16If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted, and our business would be harmed
- 17We may not be able to successfully manage our growth, and if we are not able to grow efficiently, our business, financial condition and results of operations could be harmed
- 18Our business experiences seasonality, which may cause fluctuations in our revenue and results of operations
- 19If our new solutions and services are not adopted by our clients or members, or if we fail to innovate and develop new offerings that are adopted by our clients, our revenue and results of operations may be adversely affected
- 20If we fail to adapt and respond effectively to the changing medical landscape, changing laws, regulations or government actions or enforcement priorities, or changing client needs, requirements or preferences, our offerings may become less competitive
- 21If we fail to maintain and enhance our brand, our ability to expand our client base will be impaired, and our business, financial condition and results of operations may suffer
- 22If we fail to retain members of our management team or other key employees or fail to attract additional qualified personnel, our business and future growth may be negatively impacted
- 23Any litigation against us could be costly and time-consuming to defend and could harm our business, financial condition and results of operations
- 24We are exposed to credit risk from our members
- 25Our business with government entities is subject to a number of challenges and risks
- 26Failure to enforce our intellectual property rights could impair our ability to protect our proprietary technology and our brand66% rewritten
- 27We may not be able to utilize a portion of our net operating loss carryforwards, which could adversely affect our profitability
- 28Changes in our effective tax rate or tax liabilities may have an adverse effect on our results of operations31% rewritten
- 29Certain U.S. state tax authorities may assert that we have a state nexus and seek to impose state and local taxes, which could adversely affect our results of operations
- 30Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States
- 31If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected
Risks Related to Our Relationships with Third Parties
- 32Our business depends on our ability to maintain our Center of Excellence network of high-quality fertility specialists and other healthcare providers. If we are unable to do so, our future growth would be limited and our business, financial condition and results of operations would be harmed
- 33Our growth depends in part on the success of our strategic relationships with, and monitoring of, third parties, including channel partners and vendors, as well as insurance carriers
- 34If we fail to maintain an efficient pharmacy distribution network or if there is a disruption to our network of specialty pharmacies or their supply chains or business economics, our business, financial condition and results of operations could suffer
- 35If we lose our relationship with one or more key pharmacy program partners, or if the rebates provided by pharmacy program partners decline, our business and results of operations could be adversely affected
- 36Our marketing efforts depend on our ability to maintain our relationships with benefits consultants and receive positive references from our existing clients, channel partners and benefits consultants
Risks Related to Legal and Regulatory Requirements
- 37We operate in a highly regulated industry and must comply with a significant number of new and evolving legal and regulatory requirements, as well as complex judicial mandates, which could have an adverse impact on our business71% rewritten
- 38Changes in State and Federal Laws Related to Reproductive Rights and Fertility Benefits
- 39HIPAA Privacy and Security Requirements
- 40Other Data Privacy and Cybersecurity Requirements
- 41Data Protection and Breaches
- 42State Corporate Practice and Fee-Splitting Prohibitions
- 43Restrictions on Communication
- 44We are part of the broader healthcare industry and subject to increasing scrutiny, disclosure requirements and regulation within our business, including with respect to Progyny Rx’s PBM operations, which may adversely affect our business, financial condition and results of operations27% rewritten
- 45As a result of being a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting, and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock
- 46We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject us to criminal or civil liability and harm our business, financial condition and results of operations
- 47Changing rules and regulations regarding environmental, social and governance practices and reporting could cause us to incur additional costs, devote additional resources and expose us to additional risks, which could adversely impact our reputation, or otherwise adversely impact our business
Risks Related to Ownership of Our Common Stock
- 48Our stock price may experience volatility, and the value of our common stock may decline
- 49An active trading market for our common stock may not be sustained86% rewritten
- 50Future sales of our common stock in the public market, including in connection with financings, acquisitions, our equity incentive plan or otherwise, could cause the market price of our common stock to decline
- 51If securities or industry analysts do not publish research, or publish unfavorable or inaccurate research, about our business, the market price and trading volume of our common stock could decline
- 52We do not intend to pay dividends for the foreseeable future, and, as a result, your ability to receive a return on your investment will depend on appreciation in the price of our common stock
- 53Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock
Other Progyny 10-Ks
- FY2024 10-K risk factors56 risks
Progyny operates in a highly competitive fertility benefits market dominated by its Smart Cycle model and Progyny Rx solution. Growth depends on retaining tech industry clients, expanding the Center of Excellence network, and managing pharmacy distribution partnerships. The business faces intense regulatory scrutiny regarding reproductive rights, healthcare laws, and state tax nexus rules.
Filed Mar 03, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.